You are here: Industry Insights > cabotegravir

News List

FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention FDA
December 22, 2021
Today, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds) for pre-exposure prophylaxis (PrEP)...
NICE approves first long-acting jab for HIV to replace daily pills PharmaTimes
November 22, 2021
NICE has published draft guidance recommending the first long-acting injectable treatment for HIV-1 infection in adults, offering an alternative to adults living with HIV who have to take daily antiretroviral drugs.
NICE approves first long-acting injectable HIV-1 treatment EuropeanPharmaceuticalReview
November 19, 2021
The National Institute of Health and Care Excellence (NICE) has announced the publication of draft guidance recommending cabotegravir, the first long-acting injectable treatment for HIV-1 infection in adults.
ViiV Healthcare starts rolling submission of cabotegravir for HIV prevention pharmaceutical-technology
May 06, 2021
ViiV Healthcare has begun a rolling submission of a new drug application (NDA) with the US Food and Drug Administration (FDA) for its long-acting cabotegravir to prevent human immunodeficiency virus (HIV) or pre-exposure prophylaxis (PrEP).
Sales of injectable anti-HIV therapeutics will reach $2 billion in 2029: GlobalData expresspharma
March 01, 2021
Cabotegravir-based therapies are projected to generate 79 per cent of the sales of injectable therapeutics in the HIV market in 2029.
US FDA approves ViiV Healthcare’s Cabenuva as complete long-acting regimen for HIV treatment expresspharma
January 22, 2021
Cabenuva allows virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine to maintain viral suppression with 12 dosing days per year.
First long-acting HIV treatment approved in Europe europeanpharmaceuticalreview
January 05, 2021
The European Commission approval of the long-acting injectable HIV treatment could transform the lives of people living with the disease.
ViiV’s cabotegravir scores breakthrough designation for HIV prevention pharmatimes
November 19, 2020
GlaxoSmithKline subsidiary ViiV Healthcare has announced that its long-acting injectable cabotegravir has scored a breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for HIV prevention.
ViiV’s long-acting HIV drug beats standard of care in prevention study pharmatimes
November 12, 2020
ViiV Healthcare has announced that its long-acting injectable cabotegravir for HIV prevention demonstrated superiority compared to the current standard of treatment for women.
Final data on ViiV's cabotegravir show impressive HIV PrEP pharmatimes
July 09, 2020
ViiV's investigational, long-acting injectable cabotegravir was found to be 66% more effective than daily pills in preventing HIV-1 acquisition, according to final analysis of data from the HPTN 083 study.

Previous page 1 2 Next page